1. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology(11 Suppl 5):S21-S23
2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology(5):384-386. https://10.1212/01.wnl.0000247740.47667.03
3. Zhang XM, Yin M, Zhang MH (2014) Cell-based assays for Parkinson's disease using differentiated human LUHMES cells. Acta Pharmacol Sin(7):945-956. https://10.1038/aps.2014.36
4. Arnot CJ, Gay NJ, Gangloff M (2010) Molecular mechanism that induces activation of Spatzle, the ligand for the Drosophila Toll receptor. J Biol Chem(25):19502-19509. https://10.1074/jbc.M109.098186
5. Schmidt F, Champy P, Seon-Meniel B, Franck X, Raisman-Vozari R, Figadere B (2009) Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture. Plos One(7):e6215. https://10.1371/journal.pone.0006215
6. Son JH, Chun HS, Joh TH, Cho S, Conti B, Lee JW (1999) Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J Neurosci(1):10-20
7. Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. Acta Neurol Scand Suppl:49-54
8. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis(2):404-412. https://10.1016/j.nbd.2005.08.002
9. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res(1-2):187-193. https://10.1016/s0006-8993(01)02681-6
10. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci(5):1763-1771
11. Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray CK, Walker Z, Turkheimer FE, Brooks DJ (2013) Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacol(6):938-949. https://10.1038/npp.2012.255
12. Schroder K, Tschopp J (2010) The inflammasomes. Cell(6):821-832. https://10.1016/j.cell.2010.01.040
13. Rathinam VA, Fitzgerald KA (2016) Inflammasome complexes: Emerging mechanisms and effector functions. Cell(4):792-800. https://10.1016/j.cell.2016.03.046
14. Jo EK, Kim JK, Shin DM, Sasakawa C (2016) Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol(2):148-159. https://10.1038/cmi.2015.95
15. Guo H, Callaway JB, Ting JP (2015) Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat Med(7):677-687. https://10.1038/nm.3893
16. Ozaki E, Campbell M, Doyle SL (2015) Targeting the NLRP3 inflammasome in chronic inflammatory diseases: Current perspectives. J Inflamm Res:15-27. https://10.2147/JIR.S51250
17. Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, Son J, Yu JW (2019) MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ(2):213-228. https://10.1038/s41418-018-0124-5
18. Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C (2015) NLRP3 inflammasome and its inhibitors: A review. Front Pharmacol:262. https://10.3389/fphar.2015.00262
19. Broz P, Dixit VM (2016) Inflammasomes: Mechanism of assembly, regulation and signalling. Nat Rev Immunol(7):407-420. https://10.1038/nri.2016.58
20. Gurung P, Lukens JR, Kanneganti TD (2015) Mitochondria: Diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med(3):193-201. https://10.1016/j.molmed.2014.11.008
21. Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC, Salter RD (2013) Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol(10):5230-5238. https://10.4049/jimmunol.1301490
22. Sorbara MT, Girardin SE (2011) Mitochondrial ROS fuel the inflammasome. Cell Res(4):558-560. https://10.1038/cr.2011.20
23. Vanaja SK, Rathinam VA, Fitzgerald KA (2015) Mechanisms of inflammasome activation: Recent advances and novel insights. Trends Cell Biol(5):308-315. https://10.1016/j.tcb.2014.12.009
24. Yao RW, Wang Y, Chen LL (2019) Cellular functions of long noncoding RNAs. Nat Cell Biol(5):542-551. https://10.1038/s41556-019-0311-8
25. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature(7301):1033-1038. https://10.1038/nature09144
26. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell(3):353-358. https://10.1016/j.cell.2011.07.014
27. Elkouris M, Kouroupi G, Vourvoukelis A, Papagiannakis N, Kaltezioti V, Matsas R, Stefanis L, Xilouri M, Politis PK (2019) Long non-coding RNAs associated with Neurodegeneration-Linked genes are reduced in parkinson's disease patients. Front Cell Neurosci:58. https://10.3389/fncel.2019.00058
28. Hadjicharalambous MR, Roux BT, Feghali-Bostwick CA, Murray LA, Clarke DL, Lindsay MA (2018) Long non-coding RNAs are central regulators of the IL-1beta-Induced inflammatory response in normal and idiopathic pulmonary lung fibroblasts. Front Immunol:2906. https://10.3389/fimmu.2018.02906
29. Askarian-Amiri ME, Crawford J, French JD, Smart CE, Smith MA, Clark MB, Ru K, Mercer TR, Thompson ER, Lakhani SR, Vargas AC, Campbell IG, Brown MA, Dinger ME, Mattick JS (2011) SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. Rna(5):878-891. https://10.1261/rna.2528811
30. Zhang Y, Sun L, Xuan L, Pan Z, Li K, Liu S, Huang Y, Zhao X, Huang L, Wang Z, Hou Y, Li J, Tian Y, Yu J, Han H, Liu Y, Gao F, Zhang Y, Wang S, Du Z, Lu Y, Yang B (2016) Reciprocal changes of circulating long Non-Coding RNAs ZFAS1 and CDR1AS predict acute myocardial infarction. Sci Rep:22384. https://10.1038/srep22384
31. Wu T, Wu D, Wu Q, Zou B, Huang X, Cheng X, Wu Y, Hong K, Li P, Yang R, Li Y, Cheng Y (2017) Knockdown of long Non-Coding RNA-ZFAS1 protects cardiomyocytes against acute myocardial infarction via Anti-Apoptosis by regulating miR-150/CRP. J Cell Biochem(10):3281-3289. https://10.1002/jcb.25979
32. Ye Y, Gao X, Yang N (2018) LncRNA ZFAS1 promotes cell migration and invasion of fibroblast-like synoviocytes by suppression of miR-27a in rheumatoid arthritis. Hum Cell(1):14-21. https://10.1007/s13577-017-0179-5
33. Dong D, Mu Z, Wang W, Xin N, Song X, Shao Y, Zhao C (2017) Prognostic value of long noncoding RNA ZFAS1 in various carcinomas: A meta-analysis. Oncotarget(48):84497-84505. https://10.18632/oncotarget.21100
34. Makkar R, Behl T, Bungau S, Kumar A, Arora S (2020) Understanding the role of inflammasomes in rheumatoid arthritis. Inflammation(6):2033-2047. https://10.1007/s10753-020-01301-1
35. He A, He S, Li X, Zhou L (2019) ZFAS1: A novel vital oncogenic lncRNA in multiple human cancers. Cell Prolif(1):e12513. https://10.1111/cpr.12513
36. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol(2):136-140. https://10.1038/ni.1831
37. Filhoulaud G, Benhamed F, Pagesy P, Bonner C, Fardini Y, Ilias A, Movassat J, Burnol AF, Guilmeau S, Kerr-Conte J, Pattou F, Issad T, Postic C (2019) O-GlcNacylation links TxNIP to inflammasome activation in pancreatic beta cells. Front Endocrinol (Lausanne):291. https://10.3389/fendo.2019.00291
38. Lopez-Castejon G (2020) Control of the inflammasome by the ubiquitin system. Febs J(1):11-26. https://10.1111/febs.15118
39. Wang H, Cai J (2017) The role of microRNAs in heart failure. Biochim Biophys Acta Mol Basis Dis(8):2019-2030. https://10.1016/j.bbadis.2016.11.034
40. Dong D, Mu Z, Zhao C, Sun M (2018) ZFAS1: A novel tumor-related long non-coding RNA. Cancer Cell Int:125. https://10.1186/s12935-018-0623-y
41. Akula N, Barb J, Jiang X, Wendland JR, Choi KH, Sen SK, Hou L, Chen DT, Laje G, Johnson K, Lipska BK, Kleinman JE, Corrada-Bravo H, Detera-Wadleigh S, Munson PJ, Mcmahon FJ (2014) RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. Mol Psychiatry(11):1179-1185. https://10.1038/mp.2013.170
42. Barry G (2014) Integrating the roles of long and small non-coding RNA in brain function and disease. Mol Psychiatry(4):410-416. https://10.1038/mp.2013.196
43. Johnson R, Richter N, Jauch R, Gaughwin PM, Zuccato C, Cattaneo E, Stanton LW (2010) Human accelerated region 1 noncoding RNA is repressed by REST in Huntington's disease. Physiol Genomics(3):269-274. https://10.1152/physiolgenomics.00019.2010
44. Ng SY, Lin L, Soh BS, Stanton LW (2013) Long noncoding RNAs in development and disease of the central nervous system. Trends Genet(8):461-468. https://10.1016/j.tig.2013.03.002
45. Sarkar SN, Russell AE, Engler-Chiurazzi EB, Porter KN, Simpkins JW (2019) MicroRNAs and the genetic nexus of brain aging, neuroinflammation, neurodegeneration, and brain trauma. Aging Dis(2):329-352. https://10.14336/AD.2018.0409
46. Wang S, Zhang X, Guo Y, Rong H, Liu T (2017) The long noncoding RNA HOTAIR promotes Parkinson's disease by upregulating LRRK2 expression. Oncotarget(15):24449-24456. https://10.18632/oncotarget.15511
47. Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, Finch CE, St LGR, Kenny PJ, Wahlestedt C (2008) Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med(7):723-730. https://10.1038/nm1784
48. Chakrabarti S, Mohanakumar KP (2016) Aging and neurodegeneration: A tangle of models and mechanisms. Aging Dis(2):111-113. https://10.14336/AD.2016.0312
49. Marki S, Goblos A, Szlavicz E, Torok N, Balicza P, Bereznai B, Takats A, Engelhardt J, Klivenyi P, Vecsei L, Molnar MJ, Nagy N, Szell M (2018) The rs13388259 intergenic polymorphism in the genomic context of the BCYRN1 gene is associated with parkinson's disease in the hungarian population. Parkinsons Dis:9351598. https://10.1155/2018/9351598
50. Ni Y, Huang H, Chen Y, Cao M, Zhou H, Zhang Y (2017) Investigation of long non-coding RNA expression profiles in the substantia nigra of parkinson's disease. Cell Mol Neurobiol(2):329-338. https://10.1007/s10571-016-0373-0
51. Saracchi E, Fermi S, Brighina L (2014) Emerging candidate biomarkers for Parkinson's disease: A review. Aging Dis(1):27-34. https://10.14366/AD.2014.050027
52. Soreq L, Guffanti A, Salomonis N, Simchovitz A, Israel Z, Bergman H, Soreq H (2014) Long non-coding RNA and alternative splicing modulations in Parkinson's leukocytes identified by RNA sequencing. Plos Comput Biol(3):e1003517. https://10.1371/journal.pcbi.1003517
53. Jellinger KA (2012) Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. Mov Disord(1):8-30. https://10.1002/mds.23795
54. Rocha NP, de Miranda AS, Teixeira AL (2015) Insights into neuroinflammation in parkinson's disease: From biomarkers to Anti-Inflammatory based therapies. Biomed Res Int:628192. https://10.1155/2015/628192
55. Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, Robertson A, Butler MS, Rowe DB, O'Neill LA, Kanthasamy AG, Schroder K, Cooper MA, Woodruff TM (2018) Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med(465). https://10.1126/scitranslmed.aah4066
56. Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y):575-590. https://10.1016/j.trci.2018.06.014
57. Moss DW, Bates TE (2001) Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur J Neurosci(3):529-538. https://10.1046/j.1460-9568.2001.01418.x
58. Nayak D, Roth TL, Mcgavern DB (2014) Microglia development and function. Annu Rev Immunol:367-402. https://10.1146/annurev-immunol-032713-120240
59. Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, Chasovskikh S, Mhyre TR, Maguire-Zeiss KA (2011) Alpha-Synuclein alters Toll-Like receptor expression. Front Neurosci:80. https://10.3389/fnins.2011.00080
60. Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M (2013) Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. Plos One(1):e55375. https://10.1371/journal.pone.0055375
61. Sarkar S, Malovic E, Harishchandra DS, Ghaisas S, Panicker N, Charli A, Palanisamy BN, Rokad D, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG (2017) Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson's disease. NPJ Parkinsons Dis:30. https://10.1038/s41531-017-0032-2
62. von Herrmann KM, Salas LA, Martinez EM, Young AL, Howard JM, Feldman MS, Christensen BC, Wilkins OM, Lee SL, Hickey WF, Havrda MC (2018) NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease. NPJ Parkinsons Dis:24. https://10.1038/s41531-018-0061-5
63. Yoshihara E, Masaki S, Matsuo Y, Chen Z, Tian H, Yodoi J (2014) Thioredoxin/Txnip: Redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol:514. https://10.3389/fimmu.2013.00514
64. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, Yodoi J (1999) Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem(31):21645-21650. https://10.1074/jbc.274.31.21645
65. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, Vatner SF, Sadoshima J (2008) A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell(6):978-993. https://10.1016/j.cell.2008.04.041
66. Jeon JH, Lee KN, Hwang CY, Kwon KS, You KH, Choi I (2005) Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res(11):4485-4489. https://10.1158/0008-5472.CAN-04-2271
67. Yamaguchi F, Takata M, Kamitori K, Nonaka M, Dong Y, Sui L, Tokuda M (2008) Rare sugar D-allose induces specific up-regulation of TXNIP and subsequent G1 cell cycle arrest in hepatocellular carcinoma cells by stabilization of p27kip1. Int J Oncol(2):377-385
68. Yoshihara E, Fujimoto S, Inagaki N, Okawa K, Masaki S, Yodoi J, Masutani H (2010) Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity. Nat Commun:127. https://10.1038/ncomms1127